Commentary on “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.” Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI: J Clin Oncol 2013;31(4):412–9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.

Autor: Trump, Donald L.
Zdroj: In Urologic Oncology: Seminars and Original Investigations November 2013 31(8):1848-1848
Databáze: ScienceDirect
Externí odkaz: